Abivax (ABVX) is trading higher as the market re-anchors on the company’s next major catalyst: topline results from the Phase 3 ABTECT-UC maintenance trial of obefazimod in moderately to severely active ulcerative colitis, guided for late Q2 2026. Sentiment has been supported by a recent Data Safety Monitoring Board review dated March 18, 2026 that reported no new safety signals, reinforcing expectations that the pivotal maintenance program remains intact heading into the readout.

After the induction-stage Phase 3 results previously put obefazimod on investors’ radar, the maintenance dataset is positioned as the key swing factor for durability and regulatory confidence. Abivax has indicated it is preparing for a potential U.S. filing in late 2026, making the late-Q2 maintenance topline update the central near-term value driver for the stock.

In its March 23, 2026 full-year 2025 update, Abivax highlighted a strengthened balance sheet with cash, cash equivalents, and short-term investments of €530.4 million as of December 31, 2025, and projected runway into Q4 2027. The company also pointed to commercialization-facing execution steps, including a new Chief Commercial Officer hire, which can matter for investor positioning as the story shifts from clinical proof to launch preparation.

ABVX trading is likely to remain headline-sensitive into the late-Q2 2026 window as investors track any additional trial updates, regulatory interactions, or commercial readiness signals. With a binary-ish catalyst ahead, positioning can amplify day-to-day moves even without fresh company-specific news, particularly as traders anticipate the maintenance topline event.